

29 August 2023

Timeline extended for Osteopore and CellHeal to reach definitive agreements for Term Sheet

Highlights

- Osteopore and CellHeal have agreed to extend the timeline to finalise definitive agreements to 31 October 2023
-

Osteopore Limited (ASX: OSX; Osteopore or Company) - a Singapore-based and Australian-listed regenerative medicine company that is seeking to commercialise products that enable natural bone healing across multiple therapeutic areas - is pleased to announce that an agreement has been reached with CellHeal Pty Ltd (**CellHeal**) to extend the timeline for definitive agreements.

On 25 July 2023, Osteopore and CellHeal announced the signing of a non-binding term sheet (**Term Sheet**), providing a framework to negotiate definitive agreements for the licensing of select Osteopore intellectual properties (IP) and technologies – including 3D printed biomaterials for bone, cartilage and tissue regeneration – to CellHeal, a recognised partner that specialises in commercialising products for market entry into China.

The timeline has been extended to 31 October 2023, providing Osteopore and CellHeal with additional time to finalise the definitive agreements.

Osteopore will keep the market updated on the definitive agreements in accordance with its continuous disclosure obligations.



ENDS

This announcement dated 29 August 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Ltd is an Australian-Singaporean medical technology company aiming to commercialise products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About CellHeal Therapeutics

CellHeal is a biopharmaceutical company focused on developing Cell Gene Therapy medicine and personalised treatments. The company engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. CellHeal utilises its industry expertise and rigorous analysis to support Australian CGT leaders accelerate and commercialise products for market entry into Greater China.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on various factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

